Healthy volunteers help uncover drug interaction secrets

NCT ID NCT07439250

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 study looked at how the antifungal drug fluconazole changes the way the body handles the experimental cancer drug olomorasib. Fifteen healthy volunteers took olomorasib alone and then with fluconazole, and researchers measured drug levels in their blood. The goal was to understand if fluconazole affects how much olomorasib gets into the bloodstream and how quickly it is eliminated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olomorasib (LY3537982) and fluconazole
What this could lead to: If successful, this study will help doctors understand how to safely dose olomorasib when taken with fluconazole, potentially improving treatment for future patients.
What could go wrong: This is a very early, small study in healthy people, not patients. It only measures drug levels in the blood, not whether the drug works or is safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.